1
|
Daudén E, Escario E, Martos-Cabrera L, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera R, de la Cueva P, Martorell A, Ballesca F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Riera-Monroig J, Garrido J, Llamas-Velasco M. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting. Int J Dermatol 2024; 63:503-511. [PMID: 38168847 DOI: 10.1111/ijd.16915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 10/16/2023] [Accepted: 11/08/2023] [Indexed: 01/05/2024]
Abstract
BACKGROUND Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. OBJECTIVE The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications. METHODS A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow-up. RESULTS In 63/347 patients with an initial standard dose regimen, SEC-DR was tried at any moment in 18.2% of them after sustained response. In 51 patients, the interval between administrations was increased while in 12 patients, monthly dose was reduced to 150 mg. Successful SEC-DR was achieved in 77.8% of the patients, with sustained PASI response to the end of the study. Survival of secukinumab treatment and safety profile were not compromised by DR. The use of DR saved 33% of the cost, including failures in which standard treatment was resumed. LIMITATIONS The proper of the study designed and the arbitrary definition of "DR success." CONCLUSION Off-label SEC-DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long-term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving.
Collapse
Affiliation(s)
- Esteban Daudén
- Hospital Universitario de la Princesa. Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain
| | - Elena Escario
- Hospital Universitario de la Princesa. Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain
| | - Luisa Martos-Cabrera
- Hospital Universitario de la Princesa. Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain
| | - Susana Armesto
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - David Vidal
- Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain
| | - Eva Vilarrasa
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | | | - Ferran Ballesca
- Hospital Universitario Germans Trias i Pujol, Barcelona, Spain
| | - Isabel Belinchón
- Hospital General Universitario de Alicante - ISABIAL, Alicante, Spain
| | | | | | | | - J Pujol-Montcusí
- Hospital Universitario de Tarragona "Joan XXIII", Tarragona, Spain
| | - Laura Salgado
- Complejo Hospitalario Universitario, Pontevedra, Spain
| | | | | | | | - R Feltes
- Hospital Universitario la Paz, Madrid, Spain
| | | | | | - Mar Llamas-Velasco
- Hospital Universitario de la Princesa. Instituto de Investigación Sanitaria la Princesa (IIS-IP), Madrid, Spain
| |
Collapse
|
2
|
Navarro-Guillamón PJ, Valencia-Serrano M, Suarez-Perez JA, Herrera-Acosta E. Povidone iodine gel use as a conductive and antiseptic in ultrasound-guided invasive procedures. J Am Acad Dermatol 2024:S0190-9622(24)00477-8. [PMID: 38467305 DOI: 10.1016/j.jaad.2024.01.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 01/19/2024] [Indexed: 03/13/2024]
Affiliation(s)
| | | | - Jorge Alonso Suarez-Perez
- Dermatology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Dermatology Department of Hospital Universitario Virgen de la Victoria, Faculty of Medicine, University of Málaga, Málaga, Spain
| | - Enrique Herrera-Acosta
- Dermatology Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain; Dermatology Department of Hospital Universitario Virgen de la Victoria, Faculty of Medicine, University of Málaga, Málaga, Spain
| |
Collapse
|
3
|
Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, Rivera-Díaz R, Sahuquillo-Torralba A, Llamas-Velasco M, Gómez-García FJ, Herrera-Acosta E, de la Cueva P, Baniandrés-Rodríguez O, Lopez-Estebaranz JL, Belinchón I, Ferrán M, Mateu A, Rodríguez L, Riera-Monroig J, Abalde-Pintos MT, Carretero G, García-Donoso C, Pujol-Marco C, Del Alcázar E, Santamaría-Domínguez C, Suárez-Pérez JA, Nieto-Benito LM, Ruiz-Genao DP, Salgado-Boquete L, Descalzo MÁ, García-Doval I. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry. Br J Dermatol 2024; 190:355-363. [PMID: 37846976 DOI: 10.1093/bjd/ljad382] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 10/18/2023]
Abstract
BACKGROUND Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety is the main purpose of the BIOBADADERM registry. The combination of a biologic agent and a conventional systemic drug [generally methotrexate (MTX)] is a common treatment in clinical practice. However, there is a paucity of evidence from real-world practice on the safety of such combination regimens in the treatment of psoriasis. OBJECTIVES The primary objective of this study was to ascertain whether the use of regimens combining biologic drugs with MTX in the management of moderate-to-severe psoriasis increases the risk of adverse events (AEs) or serious AEs (SAEs). We compared monotherapy using tumour necrosis factor (TNF), interleukin (IL)-17 and IL-23 inhibitors with the use of the same drugs in combination with MTX. METHODS Using data from the BIOBADADERM registry, we compared biologic monotherapies with therapies that were combined with MTX. We estimated adjusted incidence rate ratios (aIRR) using a random effects Poisson regression with 95% confidence intervals for all AEs, SAEs, infections and serious infections and other AEs by system organ class. RESULTS We analysed data from 2829 patients and 5441 treatment cycles, a total of 12 853 patient-years. The combination of a biologic with MTX was not associated with statistically significant increases in overall risk of AEs or SAEs in any treatment group. No increase in the total number of infections or serious infections in patients receiving combined therapy was observed for any group. However, treatment with a TNF inhibitor combined with MTX was associated with an increase in the incidence of gastrointestinal AEs (aIRR 2.50, 95% CI 1.57-3.98; P < 0.002). CONCLUSIONS The risk of AEs and SAEs was not significantly increased in patients with moderate-to-severe psoriasis receiving different classes of biologic drugs combined with MTX compared with those on biologic monotherapy.
Collapse
Affiliation(s)
- Juan José Lluch-Galcerá
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP. Badalona, Barcelona, Spain
- Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Barcelona, Spain
| | - Jose Manuel Carrascosa
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP. Badalona, Barcelona, Spain
- Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Barcelona, Spain
| | - Alicia González-Quesada
- Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain
| | - Raquel Rivera-Díaz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain
| | | | - Mar Llamas-Velasco
- Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-LP), Madrid,Spain
| | | | | | - Pablo de la Cueva
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | | | | | - Isabel Belinchón
- Department of Dermatology, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, Spain
| | - Marta Ferrán
- Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
| | - Almudena Mateu
- Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain
| | - Lourdes Rodríguez
- Department of Dermatology, Hospital Virgen del Rocío, Seville, Spain
| | - Josep Riera-Monroig
- Department of Dermatology, Hospital Clinic de Barcelona, UB, Barcelona, Spain
| | - M Teresa Abalde-Pintos
- Department of Dermatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | - Gregorio Carretero
- Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain
| | - Carmen García-Donoso
- Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain
| | - Conrad Pujol-Marco
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia,Spain
| | - Elena Del Alcázar
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, IGTP. Badalona, Barcelona, Spain
- Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Barcelona, Spain
| | - Cristina Santamaría-Domínguez
- Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-LP), Madrid,Spain
| | | | - Lula María Nieto-Benito
- Department of Dermatology, CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | | | - Laura Salgado-Boquete
- Department of Dermatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
| | | | - Ignacio García-Doval
- Research Unit, Spanish Academy of Dermatology and Venereology, Madrid, Spain
- Department of Dermatology, Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
| |
Collapse
|
4
|
Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A, Baniandrés Rodríguez O, Herrera-Acosta E, Rivera-Diaz R, Ferran M, Sánchez-Carazo JL, Riera-Monroig J, Pujol-Montcusí J, Vidal D, de la Cueva P, García-Bustinduy M, Ruiz-Villaverde R, Ballescà F, Llamas-Velasco M, Navares M, Palomar-Moreno I, Sánchez-García I, García-Martínez J, Novalbos J, Zubiaur P, Abad-Santos F, Daudén-Tello E, de la Fuente H. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice. J Eur Acad Dermatol Venereol 2023. [PMID: 38153843 DOI: 10.1111/jdv.19782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Accepted: 11/22/2023] [Indexed: 12/30/2023]
Abstract
BACKGROUND Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation. OBJECTIVE To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting. METHODS We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed. RESULTS A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR-146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83-0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes. CONCLUSION We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non-response to this drug in patients with plaque psoriasis.
Collapse
Affiliation(s)
- E Muñoz-Aceituno
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - B Butrón-Bris
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - M C Ovejero-Benito
- Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU, CEU Universities Madrid, Madrid, Spain
| | - A Sahuquillo-Torralba
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - O Baniandrés Rodríguez
- Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - E Herrera-Acosta
- Department of Dermatology, Hospital Virgen de la Victoria, Málaga, Spain
| | - R Rivera-Diaz
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M Ferran
- Department of Dermatology, Hospital del Mar, Barcelona, Spain
| | - J L Sánchez-Carazo
- Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain
| | - J Riera-Monroig
- Department of Dermatology, Hospital Clínic i Provincial, Barcelona, Spain
| | - J Pujol-Montcusí
- Department of Dermatology, Hospital Universitario "Joan XXIII", Tarragona, Spain
| | - D Vidal
- Department of Dermatology, Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain
| | - P de la Cueva
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - M García-Bustinduy
- Department of Dermatology, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain
| | - R Ruiz-Villaverde
- Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain
| | - F Ballescà
- Department of Dermatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain
| | - M Llamas-Velasco
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - M Navares
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain
| | - I Palomar-Moreno
- Unit of Molecular Biology, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - I Sánchez-García
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - J García-Martínez
- Hospital Universitario del Niño Jesús, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - J Novalbos
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain
| | - P Zubiaur
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain
| | - F Abad-Santos
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria La Princesa, Universidad Autónoma de Madrid, Madrid, Spain
| | - E Daudén-Tello
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| | - H de la Fuente
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
- Unit of Molecular Biology, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
| |
Collapse
|
5
|
de Gálvez MV, Castillo-Muñoz RM, López-Navarro N, López-Jiménez P, Navarrete-de Gálvez E, Bosch-García R, Herrera-Acosta E, Aguilera J. Summer and spring elbow rashes is a variant of polymorphous light eruption: confirmation by photoprovocation and histopathology in a series of five cases. Front Med (Lausanne) 2023; 10:1260514. [PMID: 37928475 PMCID: PMC10625400 DOI: 10.3389/fmed.2023.1260514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 09/14/2023] [Indexed: 11/07/2023] Open
Abstract
Background Summer and spring eruptions on the elbows are a variant of polymorphous light eruption described on clinical and histopathological grounds; however, to our knowledge, they have not been confirmed by photobiological studies. Objective Based on photobiological studies, this study aimed to demonstrate the involvement of ultraviolet-A (UVA) radiation in this variant of polymorphous light eruption occurring exclusively on the elbows. Methods A series of five patients with polymorphous light eruption lesions on the elbows were included in our study. All patients underwent phototesting and photoprovocation of the skin lesions after exposure to a UVA light source [Philips UVA HPA lamp (400 W)]. All patients underwent punch biopsy and histopathological and immunohistochemical studies with anti-CD123. Results In all the cases, UVA irradiation caused the appearance of skin lesions on the elbows with characteristic polymorphous light eruption. Histological data showed edema in the superficial dermis and a perivascular lymphocytic infiltrate compatible with polymorphous light eruption. Immunohistochemical staining for CD1-23 showed negative results. Conclusions For the first time, photobiological photoprovocation studies demonstrated that repeated exposure to UVA radiation leads to the generation of skin lesions on the elbows, which are clinically and histologically consistent with summer and spring eruptions, confirming that elbow rash is a variant of polymorphous light eruption.
Collapse
Affiliation(s)
- María Victoria de Gálvez
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
| | | | - Norberto López-Navarro
- Dermatology Service, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
| | | | - Enrique Navarrete-de Gálvez
- Project Engineering Area, Department of Graphic Expression Design and Projects, School of Engineering, University of Málaga, Málaga, Spain
| | - Ricardo Bosch-García
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
- Dermatology Service, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
| | - Enrique Herrera-Acosta
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
- Dermatology Service, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
| | - José Aguilera
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
| |
Collapse
|
6
|
Ruiz-Villaverde R, Herrera-Acosta E, Ruiz de Casas A, Villegas-Romero IM, Moreno-Suárez FG, Vílchez-Márquez F, Galán-Gutiérrez M, Vázquez-Bayo MC, Cases-Mérida S, Almazán-Fernández FM. Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice. J Clin Med 2023; 12:5631. [PMID: 37685698 PMCID: PMC10488851 DOI: 10.3390/jcm12175631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 08/25/2023] [Accepted: 08/28/2023] [Indexed: 09/10/2023] Open
Abstract
INTRODUCTION Locally advanced basal cell carcinoma (LA-BCC) is defined as that BCC in which there is radiological confirmation of invasion of certain neighboring structures in depth and also, usually, a BCC that is of a sufficient size and invasion (although there is no radiological demonstration of deep invasion) in which surgery and radiotherapy are not adequate, are insufficient or are contraindicated to achieve the cure of the tumor, either due to characteristics of the tumor itself or of the patient. Sonidegib is indicated for the treatment of adult patients with locally advanced basal cell carcinoma that is not amenable to curative surgery or radiotherapy. MATERIAL AND METHODS This is a retrospective, multicenter and descriptive study in nine centers in Andalusia, Spain. Patients treated with sonidegib for >3 months for locally advanced BCC were included from 1 January 2021 to 1 January 2023. Epidemiological, efficacy and safety data were collected. RESULTS In the present study, a total of 38 patients were included, with a median age of 76.23 years (range 40-101). Prior treatment was surgery (31.57%; n = 25), radiotherapy (15.78%; n = 6), vismodegib (31.57%; n = 12). Eleven patients had not received prior treatment. LA-BCC were located in the cephalic pole, face or scalp. There was a total response in 9/38 patients (23.7%), partial response in 25/38 patients (65.8%) and no response in 4 patients (10.52%). In 6/34 patients, the dose was reduced to 200 mg every other day until it was discontinued due to adverse effects. The main adverse effects reported were dysgeusia (n = 8), asthenia (n = 8), = 6), muscle spasms (n = 6), alopecia (n = 4) and gastrointestinal intolerance (n = 4). DISCUSSION Sonidegib is the second iHh authorized for the treatment of adult patients with locally advanced BCC who are not amenable to curative surgery or radiotherapy, based on the results of the phase II clinical trial, BOLT. Sonidegib shows good effectiveness and an acceptable safety profile in routine clinical practice in the sample presented.
Collapse
Affiliation(s)
- Ricardo Ruiz-Villaverde
- Hospital Universitario San Cecilio, Instituto Biosanitario de Granada, Ibs, 18016 Granada, Spain;
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Martos-Cabrera L, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, de la Cueva P, Martorell-Calatayud A, Ballescá F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado-Boquete L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Alsina M, Daudén E. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting. Int J Dermatol 2023; 62:e146-e149. [PMID: 35867958 DOI: 10.1111/ijd.16365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 04/18/2022] [Accepted: 06/29/2022] [Indexed: 11/29/2022]
Affiliation(s)
| | | | - Susana Armesto
- Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - David Vidal
- Hospital de Sant Joan Despí Moisés Broggi, Barcelona, Spain
| | - Eva Vilarrasa
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | | | - Ferran Ballescá
- Hospital Universitario Germans Trias i Pujol, Barcelona, Spain
| | - Isabel Belinchón
- Hospital General Universitario de Alicante - ISABIAL, Alicante, Spain
| | | | | | | | | | | | | | | | | | - R Feltes
- Hospital Universitario la Paz, Madrid, Spain
| | - M Alsina
- Hospital Clínic i Provincial, Barcelona, Spain
| | | |
Collapse
|
8
|
Chicharro P, Llamas-Velasco M, Armesto S, Herrera-Acosta E, Vidal D, Vilarrasa E, Rivera R, De la Cueva P, Martorell A, Ballescà F, Belinchón I, Carretero G, Rodríguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés O, Feltes R, Alsina M, Daudén E. Fast and sustained Improvement of Patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatol Ther 2022; 35:e15653. [PMID: 35731640 DOI: 10.1111/dth.15653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Accepted: 06/15/2022] [Indexed: 11/28/2022]
Abstract
Psoriasis is a chronic dermatological disease with great impact on patients' quality of life (QoL). The main objective of this study was to assess the impact of secukinumab treatment on different patient-reported outcomes (PROs) during a long-term follow-up in Spanish patients with moderate-to-severe psoriasis under real-world conditions. Retrospective, observational, open-label, nationwide multicenter cohort study that included patients who initiated treatment with secukinumab in daily clinical practice conditions. PROs assessing disease impact and QoL included Dermatology Life Quality Index (DLQI), Patient's Global Psoriasis Assessment, Itch Numerical Rating Scale and EuroQoL Thermometer Visual Analogue Scale. Outcomes, including PROs and Psoriasis Area and Severity Index (PASI), were assessed at months 3, 6, 12, 18 and 24 during treatment. A total of 238 patients were enrolled in the study. Patients had a mean DLQI score of 14.9 at baseline; 78.3%, 73.7% and 71.7% of them achieved a DLQI 0/1 response at months 6, 12 and 24, respectively. DLQI score was lower in the long term for naïve patients. A sharp decrease in mean DLQI was observed during the first three months, reaching a plateau that was maintained until the end of follow-up. Similar findings were observed for the rest of QoL assessments. There was a close association between improvement in QoL and skin clearance (PASI), which progressively increased during follow-up. In this study, secukinumab sustainably improved patient's QoL during a 24-month follow-up, with strongest effects in patients naïve to biological therapies and with a direct correlation with PASI improvement. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Pablo Chicharro
- Department of Dermatology, Hospital Universitario de la Princesa, Madrid
| | - Mar Llamas-Velasco
- Department of Dermatology, Hospital Universitario de la Princesa, Madrid
| | - Susana Armesto
- Department of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - David Vidal
- Department of Dermatology, Hospital de Sant Joan Despí Moisés Broggi, Barcelona
| | - Eva Vilarrasa
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona
| | - Raquel Rivera
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid
| | - Pablo De la Cueva
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid
| | | | - Ferran Ballescà
- Department of Dermatology, Hospital Universitario Germans Trias i Pujol, Barcelona
| | - Isabel Belinchón
- Department of Dermatology, Hospital General Universitario de Alicante - ISABIAL, Alicante, Spain
| | - Gregorio Carretero
- Department of Dermatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain
| | - Lourdes Rodríguez
- Department of Dermatology, Hospital Universitario Virgen del Rocío, Sevilla
| | | | - Josep Pujol-Montcusí
- Department of Dermatology, Hospital Universitario de Tarragona "Joan XXIII", Tarragona, Spain
| | - Laura Salgado
- Department of Dermatology, Complejo Hospitalario Universitario, Pontevedra, Spain
| | - Antonio Sahuquillo-Torralba
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitária La Fe, Valencia
| | - Pablo Coto-Segura
- Department of Dermatology, Hospital Vital Alvarez-Buylla de Mieres, Asturias, Spain
| | - Ofelia Baniandrés
- Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid
| | - Rosa Feltes
- Department of Dermatology, Hospital Universitario la Paz, Madrid
| | - Mercè Alsina
- Department of Dermatology, Hospital Clínic i Provincial, Barcelona
| | - Esteban Daudén
- Department of Dermatology, Hospital Universitario de la Princesa, Madrid
| |
Collapse
|
9
|
Reolid A, Armesto S, Sahuquillo-Torralba A, Torres T, Feltes R, Vilarrasa E, Belinchón I, de la Cueva P, Rodríguez L, Romero-Maté A, Vidal D, Coto-Segura P, Herrera-Acosta E, Riera-Monroig J, Salgado L, Llamas-Velasco M, Daudén E. Secukinumab is effective and safe in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. J Am Acad Dermatol 2022; 87:705-709. [PMID: 35640798 DOI: 10.1016/j.jaad.2022.05.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 11/24/2022]
Affiliation(s)
- A Reolid
- Hospital Universitario de la Princesa (Madrid, Spain)
| | - S Armesto
- Hospital Universitario Marqués de Valdecilla (Santander, Spain)
| | - A Sahuquillo-Torralba
- Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitária La Fe (Valencia, Spain)
| | - T Torres
- Department of Dermatology, Centro Hospitalar Universitário do Porto (Porto, Portugal)
| | - R Feltes
- Hospital Universitario la Paz (Madrid, Spain)
| | - E Vilarrasa
- Hospital de la Santa Creu i Sant Pau (Barcelona, Spain)
| | - I Belinchón
- Hospital General Universitario de Alicante - ISABIAL (Alicante, Spain)
| | - P de la Cueva
- Hospital Universitario Infanta Leonor (Madrid, Spain)
| | - L Rodríguez
- Hospital Universitario Virgen del Rocío (Sevilla, Spain)
| | | | - D Vidal
- Hospital de Sant Joan Despí Moisés Broggi (Barcelona, Spain)
| | - P Coto-Segura
- Hospital Vital Alvarez-Buylla de Mieres (Asturias, Spain)
| | | | | | - L Salgado
- Complejo Hospitalario Universitario (Pontevedra, Spain)
| | | | - E Daudén
- Hospital Universitario de la Princesa (Madrid, Spain)
| |
Collapse
|
10
|
Nieto Benito L, Carretero G, Rivera-Díaz R, Carrascosa J, Daudén E, de la Cueva P, Sahuquillo-Torralba A, Herrera-Acosta E, Baniandrés-Rodríguez O, Lopez-Estebaranz J, Belinchón I, Riera-Monroig J, Ferrán M, Gómez-García F, Mateu A, Rodríguez L, Vilar-Alejo J, García-Donoso C, Ballescá F, Velasco LM, Botella-Estrada R, Herrera-Ceballos E, Ruiz-Genao D, Descalzo M, García-Doval I. Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM. Actas Dermo-Sifiliográficas 2022; 113:401-406. [DOI: 10.1016/j.ad.2021.05.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 05/23/2021] [Indexed: 10/20/2022] Open
|
11
|
Gálvez END, Aguilera J, Fonda-Pascual P, de Gálvez MV, de Andrés-Díaz JR, Vidal-Asensi S, Herrera-Acosta E, Gago-Calderon A. Analysis and evaluation of the operational characteristics of a new photodynamic therapy device. Photodiagnosis Photodyn Ther 2022; 37:102719. [PMID: 35021108 DOI: 10.1016/j.pdpdt.2022.102719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2021] [Revised: 12/19/2021] [Accepted: 01/07/2022] [Indexed: 10/19/2022]
Abstract
One of the key aspects of photodynamic therapy is the light source that is used to irradiate the lesion to be treated. The devices used must ensure that their emission spectrum matches the absorption spectrum of the photosensitizer, so that treatment radiation is delivered only on the injured area, without irradiating healthy tissue at superficial or deep levels. Irradiance values must be adequate in order to avoid thermal damage, exceed the oxygen replenishment rate and avoid long treatment times. Furthermore, the device should be user-friendly, inexpensive, and able to be adapted to different photosensitizers. We have developed an easy-to-use and highly customizable device based on LED technology. Its innovative geometric design allows radiation to be delivered to a small treatment surface, since the LEDs are arranged in three arms, the configuration of which directs their radiation on the treatment point. Different high-power color LEDs are disposed on the arms, and can be independently selected based on the most effective wavelengths for exciting the different photodynamic therapy photosensitizers. We have tested the prototype in 5 different patients (1 actinic keratose, 1 actinic cheilitis, 1 superficial basal cell carcinoma and 2 Bowen's disease) and after 1-2 sessions of total cumulative dose of 25-50 J / cm2, 100% clearance of lesions were obtained. Our device can be used by any professional in the field, whether for medical or research purposes. It facilitates the development of treatment protocols and trials with different photosensitizers.
Collapse
Affiliation(s)
- Enrique Navarrete-de Gálvez
- Project Engineering Area, Department of Graphic Expression Design and Projects, University of Málaga, Málaga, Spain
| | - José Aguilera
- Photobiological Dermatology Laboratory Medical Research Centre, Department of Dermatology and Medicine, School of Medicine, University of Málaga, Málaga, Spain.
| | | | - María Victoria de Gálvez
- Photobiological Dermatology Laboratory Medical Research Centre, Department of Dermatology and Medicine, School of Medicine, University of Málaga, Málaga, Spain
| | - José Ramón de Andrés-Díaz
- Project Engineering Area, Department of Graphic Expression Design and Projects, University of Málaga, Málaga, Spain
| | | | - Enrique Herrera-Acosta
- Photobiological Dermatology Laboratory Medical Research Centre, Department of Dermatology and Medicine, School of Medicine, University of Málaga, Málaga, Spain; Dermatology Service, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - Alfonso Gago-Calderon
- Project Engineering Area, Department of Graphic Expression Design and Projects, University of Málaga, Málaga, Spain
| |
Collapse
|
12
|
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E. Ixekizumab for Patients with Plaque Psoriasis Affected by Multiple Sclerosis: Case report. Sultan Qaboos Univ Med J 2021; 21:488-490. [PMID: 34522419 PMCID: PMC8407899 DOI: 10.18295/squmj.4.2021.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 08/26/2020] [Accepted: 09/01/2020] [Indexed: 11/16/2022] Open
Abstract
Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system that shares similar immunopathogenic mechanisms with chronic plaque psoriasis, such as the overexpression of the Th17 pathway. We report a 50-year-old male patient with MS and severe chronic plaque psoriasis who presented to Hospital Virgen de la Victoria, Málaga, Spain, in 2019. He was successfully treated with ixekizumab (anti-interleukin [IL]-17A and IL-17A/F monoclonal antibody). The treatment achieved complete skin clearance (i.e. a Psoriasis Area Severity Index 100 response) with no adverse event and no evidence of progression of the neurological disease either.
Collapse
Affiliation(s)
| | | | - Jorge A Suárez-Pérez
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | | | | |
Collapse
|
13
|
Herranz P, Trasobares L, Mateu A, Martínez E, Ruiz-Villaverde R, Baniandrés O, Mataix Díaz J, Jiménez-Gómez N, Serra M, Ruiz Genao DP, Rivera N, Tercedor-Sánchez J, Garcia C, Cordey M, Herrera-Acosta E. Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study. Actas Dermosifiliogr (Engl Ed) 2021; 112:S0001-7310(21)00202-7. [PMID: 34052202 DOI: 10.1016/j.ad.2021.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 04/29/2021] [Accepted: 05/09/2021] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND AND OBJECTIVES It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as well as the outcomes obtained in clinical practice in Spain. METHODS Observational, retrospective, cross-sectional, multicenter study of patients with chronic plaque psoriasis who could be contacted 6 (±1) months after apremilast initiation. The data were obtained from medical records and questionnaires from patients and physicians. RESULTS A total of 80 patients were evaluated; at apremilast onset, they showed mean (standard deviation, SD) Psoriasis Area and Severity Index (PASI) = 8.3 (5.3), mean (SD) Dermatology Life Quality Index (DLQI) = 8.9 (6.6). At six months, 58.8% (n=47) of patients continued apremilast treatment (discontinuations due to lack of efficacy [16.3%], safety/tolerability [20.0%]). In patients continuing treatment, PASI75 was achieved by 36.7% of patients; mean (95% CI) DLQI score was 2.2 (0.7-3.6) and mean (SD) Patient Benefit Index score was 2.8 (0.8). Compliance with physicians' expectations was correlated with benefits reported by patients (r=0.636). Adverse events were reported by 56.3% of patients (the most common were diarrhoea and nausea). CONCLUSIONS Patients receiving apremilast for 6 months in Spanish clinical practice, reported substantial improvements in their quality of life (mean DLQI reduced by more than 6 points) and disease severity (PASI75 achieved by over one-third of patients), despite less skin involvement than patients who enrolled in clinical trials.
Collapse
Affiliation(s)
- P Herranz
- Hospital Universitario La Paz, Madrid, España.
| | - L Trasobares
- Hospital Universitario Príncipe de Asturias, Madrid, España
| | - A Mateu
- Hospital Universitario Doctor Peset, Valencia, España
| | - E Martínez
- Hospital Lluís Alcanyís Xàtiva, Valencia, España
| | | | - O Baniandrés
- Hospital General Universitario Gregorio Marañón, Madrid, España
| | | | | | - M Serra
- Hospital Can Misses, Illes Balears, España
| | | | - N Rivera
- Hospital de Mollet, Barcelona, España
| | | | | | - M Cordey
- Amgen Inc., Amgen (Europe) GmbH, Rotkreuz, Suiza
| | | |
Collapse
|
14
|
Munera-Campos M, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Baniandrés-Rodríguez O, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferran M, Riera-Monroig J, Rodriguez L, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Pujol-Marco C, Nieto-Benito LM, Ruiz-Genao DP, Alsina M, Descalzo MA, García-Doval I. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. J DERMATOL TREAT 2021; 33:2110-2117. [PMID: 33913796 DOI: 10.1080/09546634.2021.1922572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND Limited information is available regarding the risk of incident liver disease in patients with psoriasis receiving systemic therapies. OBJECTIVES To describe the liver safety findings of conventional and modern systemic therapies for moderate-to-severe psoriasis, and to compare the relative incidence rates of hepatic adverse events (AEs) for each drug. METHODS All the patients on the BIOBADADERM registry were included. Crude and adjusted incidence rate ratios (cIRR and aIRR, respectively) of hepatic AEs, using anti-TNF drugs as reference, were determined. Outcomes of interest were hypertransaminasemia, nonalcoholic fatty liver disease (NADFLD) and a group of other, less represented, hepatic AEs. RESULTS Our study included 3,171 patients exposed to systemic drugs (6279 treatment cycles). Incident hypertransaminasemia was the most frequent hepatic AE (incidence rate of 21 per 1000 patients-years [CI 95% CI 18-23]), followed by NAFLD (8 cases per 1000 patients-years [95% CI 6-10]). Methotrexate (aIRR 3.06 [2.31-4.4]; p = 0.000) and cyclosporine (aIRR 2.37 [1.05-5.35]; p = 0.0378) were associated with an increased risk for hypertransaminasemia when compared to anti-TNF-α agents. No differences were observed between different groups of biologics. Conventional therapies were not associated with new incident NAFLD. CONCLUSIONS Comparative information of the incidence of hepatic AEs could facilitate drug selection in moderate-to-severe psoriasis.
Collapse
Affiliation(s)
- M Munera-Campos
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - J Vilar-Alejo
- Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
| | - R Rivera
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - J M Carrascosa
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - E Daudén
- Department of Dermatology. Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain
| | - E Herrera-Acosta
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - A Sahuquillo-Torralba
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - F J Gómez-García
- Department of Dermatology, Hospital Universitario Reina Sofía, Cordoba, Spain
| | - O Baniandrés-Rodríguez
- Department of Dermatology, CEIMI Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - P de la Cueva
- Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - J L López-Estebaranz
- Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - I Belinchón
- Department of Dermatology, Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
| | - M Ferran
- Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
| | - J Riera-Monroig
- Department of Dermatology, Hospital Clínic de Barcelona, UB, Barcelona, Spain
| | - L Rodriguez
- Department of Dermatology, Hospital Virgen del Rocío, Sevilla, Spain
| | - G Carretero
- Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
| | - C García-Donoso
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - F Ballescá
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain
| | - M Llamas-Velasco
- Department of Dermatology. Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain
| | - E Herrera-Ceballos
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - C Pujol-Marco
- Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - L M Nieto-Benito
- Department of Dermatology, CEIMI Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - D P Ruiz-Genao
- Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - M Alsina
- Department of Dermatology, Hospital Clínic de Barcelona, UB, Barcelona, Spain
| | - M A Descalzo
- Research Unit. Fundación Piel Sana AEDV, Madrid, Spain
| | - I García-Doval
- Research Unit. Fundación Piel Sana AEDV, Madrid, Spain.,Department of Dermatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
| | | |
Collapse
|
15
|
Hernández-Fernández C, Carretero G, Rivera R, Ferrándiz C, Daudén E, Cueva P, Belinchón I, Gómez-García F, Herrera-Acosta E, Ruiz-Genao D, Ferrán M, Alsina M, Baniandrés-Rodríguez O, Sánchez-Carazo J, Botella-Estrada R, Sahuquillo-Torralba A, Rodríguez L, Vilar-Alejo J, García-Donoso C, Carrascosa J, Llamas-Velasco M, Herrera-Ceballos E, López-Estebaranz J, Pujol-Marco C, Descalzo M, Garcia-Doval I, Group A. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort. Acta Derm Venereol 2021; 101:adv00354. [PMID: 33269405 PMCID: PMC9309850 DOI: 10.2340/00015555-3711] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The effect of sex on systemic therapy for psoriasis has not been well studied. The aim of this study was to analyse a large multicentre Spanish cohort of 2,881 patients with psoriasis (58.3% males), followed from January 2008 to November 2018, to determine whether sex influences prescription, effectiveness of therapy, and the risk of adverse events. The results show that women are more likely than men to be prescribed biologics. There were no differences between men and women in effectiveness of therapy, measured in terms of drug survival. Women were more likely to develop adverse events, but the difference in risk was small and does not justify different management. Study limitations include residual confounding and the use of drug survival as a proxy for effectiveness.
Collapse
|
16
|
Ruiz-Genao D, Carretero G, Rivera R, Ferrándiz C, Daudén E, de la Cueva P, Belinchón I, Gómez-García F, Herrera-Acosta E, López-Estebaranz J, Ferrán-Farrés M, Alsina M, Baniandrés-Rodríguez O, Sánchez-Carazo J, Sahuquillo-Torralba A, Rodriguez L, Vilar-Alejo J, García-Donoso C, Carrascosa J, Llamas-Velasco M, Herrera-Ceballos E, Botella-Estrada R, Descalzo M, García-Doval I. Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm. Actas Dermo-Sifiliográficas 2020; 111:752-760. [DOI: 10.1016/j.ad.2020.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Accepted: 05/31/2020] [Indexed: 10/23/2022] Open
|
17
|
Ruiz-Genao D, Carretero G, Rivera R, Ferrándiz C, Daudén E, de la Cuev P, Belinchón I, Gómez-García F, Herrera-Acosta E, López-Estebaranz J, Ferrán-Farrés M, Alsina M, Baniandrés-Rodríguez O, Sánchez-Carazo J, Sahuquillo-Torralba A, Rodriguez L, Vilar-Alejo J, García-Donoso C, Carrascosa J, Llamas-Velasco M, Herrera-Ceballos E, Botella-Estrada R, Descalzo M, García-Doval I. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry. Actas Dermo-Sifiliográficas (English Edition) 2020. [DOI: 10.1016/j.adengl.2020.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
18
|
Martínez-García E, Arias-Santiago S, Herrera-Acosta E, Affleck A, Herrera-Ceballos E, Buendía-Eisman A. Quality of Life of Cohabitants of People Living with Acne. Acta Derm Venereol 2020; 100:adv00290. [PMID: 32945343 PMCID: PMC9274908 DOI: 10.2340/00015555-3636] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The aim of this study was to analyse the levels of anxiety, depression, and quality of life of individuals living with acne patients (cohabitants). The study included patients, cohabitants, and controls; a total of 204 participants. Patients' health-related quality of life was measured with the Dermatology Life Quality Index (DLQI), while cohabitants' quality of life was measured with the Family Dermatology Life Quality Index (FDLQI). The psychological state of all participants was measured with the Hospital Anxiety and Depression Scale (HADS). Presence of acne impaired the quality of life of 89.4% of the cohabitants. The FDLQI scores of cohabitants were significantly associated with the DLQI scores of the patients (rp = 0.294; p = 0.044). Anxiety and depression levels in cohabitants were significantly higher than in controls (p < 0.01). In conclusion, acne may have a negative impact on quality of life and psychological well-being of patients and their cohabitants.
Collapse
Affiliation(s)
- Eliseo Martínez-García
- Department of Dermatology, Virgen de la Victoria University Hospital, ES-29010 Málaga, Spain
| | | | | | | | | | | |
Collapse
|
19
|
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García E, Herrera-Ceballos E. Ixekizumab vs ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice. Dermatol Ther 2020; 33:e14202. [PMID: 32808703 DOI: 10.1111/dth.14202] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2020] [Revised: 07/27/2020] [Accepted: 08/03/2020] [Indexed: 02/06/2023]
Abstract
There is a lack of real practice studies comparing ustekinumab and ixekizumab effectiveness and safety. The main aim of this study was to compare the effectiveness and safety of both drugs used to treat moderate-to-severe psoriasis patients over 52 weeks. The secondary objective was to identify which clinical variables could have an impact on its effectiveness. A retrospective observational study was carried out, comparing the first 28 patients treated with ustekinumab after its commercialization was compared to the first 35 patients treated with ixekizumab. Although a higher level of skin clearance was achieved with ixekizumab with a PASI 90 and 100 response of 54.3% and 40% compared to 42.9% and 25% for ustekinumab, these differences were not statistically significant. Ixekizumab achieved a higher PASI 90 response in those patients with BMI > 27 (slightly overweight), which was statistically significant (P = .024). Ustekinumab had a greater survival at 52 weeks than ixekizumab, with a trend towards statistical significance (P = .052). Ixekizumab achieved higher skin clearance rates (PASI 90 and 100 response) than ustekinumab, with no statistically significant differences. However, ixekizumab should be specially considered in overweight patients.
Collapse
|
20
|
Daudén E, Carretero G, Rivera R, Ferrándiz C, Llamas-Velasco M, de la Cueva P, Belinchón I, Gómez-García FJ, Herrera-Acosta E, Ruiz-Genao DP, Ferrán-Farrés M, Alsina M, Baniandrés-Rodríguez O, Sánchez-Carazo JL, Sahuquillo-Torralba A, Fernández-Freire LR, Vilar-Alejo J, García-Donoso C, Carrascosa JM, Herrera-Ceballos E, López-Estebaranz JL, Botella-Estrada R, Segovia-Muñoz E, Descalzo MA, García-Doval I, Daudén E, Llamas-Velasco M, Carretero G, Vilar-Alejo J, Rivera R, García-Donoso C, Ferrándiz C, Carrascosa JM, Ballescá F, Cueva PDL, Belinchón I, Gómez-García FJ, Jiménez R, Herrera-Ceballos E, Herrera-Acosta E, López-Estebaranz JL, Ruiz-Genao DP, Farrés MF, Alsina M, Baniandrés O, Nieto L, Sánchez-Carazo JL, Sahuquillo-Torralba A, Botella-Estrada R, Marco CP, Fernández-Freire LR, Puchades AM, Menéndez ÁF, Salgado L, Sixto BG, Eiris N, García-Doval I, Descalzo Gallego MÁ, de Vega Martínez M. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. J Am Acad Dermatol 2020; 83:139-150. [DOI: 10.1016/j.jaad.2020.03.033] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 03/05/2020] [Accepted: 03/08/2020] [Indexed: 12/18/2022]
|
21
|
Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barrio S, Muñoz C, Llamas M, Valentí F, Mitxelena MJ, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Carrascosa JM. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol 2020; 34:2821-2829. [PMID: 32271966 DOI: 10.1111/jdv.16439] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2020] [Accepted: 03/16/2020] [Indexed: 01/10/2023]
Abstract
BACKGROUND Little has been published on the real-world effectiveness and safety of apremilast in psoriasis. OBJECTIVES To evaluate the effectiveness, safety and drug survival of apremilast at 52 weeks in patients with moderate to severe plaque psoriasis or palmoplantar psoriasis in routine clinical practice. METHODS Retrospective, multicentre study of adult patients with moderate to severe plaque psoriasis or palmoplantar psoriasis treated with apremilast from March 2016 to March 2018. RESULTS We studied 292 patients with plaque psoriasis and 85 patients with palmoplantar psoriasis. The mean (SD) Psoriasis Area and Severity Index (PASI) score was 10.7 (7.0) at baseline and 3.0 (4.2) at 52 weeks. After 12 months of treatment, 73.6% of patients had a PASI score of 3 or less. In terms of relative improvement by week 52, 49.7% of patients achieved PASI-75 (≥75% reduction in PASI score) and 26.5% achieved PASI-90. The mean physician global assessment score for palmoplantar psoriasis fell from 4.2 (5.2) at baseline to 1.3 (1.3) at week 52. Overall drug survival after 1 year of treatment with apremilast was 54.9 %. The main reasons for treatment discontinuation were loss of efficacy (23.9%) and adverse events (15.9%). Almost half of the patients in our series (47%) experienced at least one adverse event. The most common events were gastrointestinal problems. CONCLUSIONS Apremilast may be a suitable alternative for the treatment of moderate to severe psoriasis and palmoplantar psoriasis. Although the drug has a good safety profile, adverse gastrointestinal effects are common.
Collapse
Affiliation(s)
- E Del Alcázar
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| | - J A Suárez-Pérez
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - S Armesto
- Department of Dermatology, Hospital Universitario de Valdecilla, Santander, Spain
| | - R Rivera
- Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - E Herrera-Acosta
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - P Herranz
- Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain
| | - I Martín
- Department of Dermatology, Hospital Universitario Getafe, Madrid, Spain
| | - E Montesinos
- Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - M Hospital
- Department of Dermatology, Hospital Universitario Puerta de Hierro Majadahonda Madrid, Spain
| | - E Vilarrasa
- Department of Dermatology, Hospital Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - M Ferran
- Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Barcelona, Spain
| | - R Ruiz-Villaverde
- Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain
| | - A Sahuquillo-Torralba
- Department of Dermatology, Hospital Universitario y Politécnico La Fe - Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - D P Ruiz-Genao
- Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - S Pérez-Barrio
- Department of Dermatology, Hospital Universitario Basurto, Bilbao, Spain
| | - C Muñoz
- Department of Dermatology, Hospital de Granollers, Granollers, Spain
| | - M Llamas
- Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain
| | - F Valentí
- Department of Dermatology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
| | - M J Mitxelena
- Department of Dermatology, Hospital Universitario de Navarra, Pamplona, Spain
| | - A López-Ferrer
- Department of Dermatology, Hospital Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
| | - G Carretero
- Department of Dermatology, Hospital Universitario Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain
| | - D Vidal
- Department of Dermatology, Hospital Moisès Broggi, Sant Joan Despí, Spain
| | - J Mollet
- Department of Dermatology, Hospital Universitari Vall d'Hebrón, Barcelona, Spain
| | - I Belinchón
- Department of Dermatology, Hospital Universitario de Alicante -ISABIAL, UMH Alicante, Alicante, Spain
| | - J M Carrascosa
- Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona (UAB), Badalona, Spain
| |
Collapse
|
22
|
Herrera-Acosta E, Garriga-Martina GG, Suárez-Pérez JA, Martínez-García EA, Herrera-Ceballos E. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice. Dermatol Ther 2020; 33:e13313. [PMID: 32181962 DOI: 10.1111/dth.13313] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 03/05/2020] [Accepted: 03/13/2020] [Indexed: 12/20/2022]
Abstract
There are no studies which directly compare efficacy in Psoriasis Area and Severity Index (PASI) response of secukinumab and ixekizumab. The main aim of this study was to compare the efficacy and safety of both drugs used to treat moderate-to-severe psoriasis patients over 52 weeks. Secondary objectives were to identify which factors related to prior biologic treatment influenced their efficacy and analyze data obtained at 12 weeks. A retrospective observational study was carried out, in which a group of the first 59 patients treated with secukinumab after its commercialization, was compared with another group of the first 29 patients treated with ixekizumab. The PASI 75, 90, and 100 response obtained at 52 weeks was 64.4%, 49.2%, and 41.4% for secukinumab and 75.9%, 62.1%, and 41.4% for ixekizumab, respectively, with no statistically significant differences. Regarding previous biological treatment, both treatments showed a decrease in efficacy as the number of prior biologics increases. No differences were found between secukinumab and ixekizumab in bio-naïve or bio-experienced patients, with the exception of a higher PASI 75 response at week 52 for ixekizumab in those patients with two or more previous biologics (P = .039) Secukinumab and ixekizumab have demonstrated high efficacy and safety, with no statistically significant differences.
Collapse
Affiliation(s)
- Enrique Herrera-Acosta
- Department of Dermatology, Hospital Clínico Virgen de la Victoria, University of Malaga, Malaga, Spain
| | - Gustavo G Garriga-Martina
- Department of Dermatology, Hospital Clínico Virgen de la Victoria, University of Malaga, Malaga, Spain
| | - Jorge A Suárez-Pérez
- Department of Dermatology, Hospital Clínico Virgen de la Victoria, University of Malaga, Malaga, Spain
| | - Eliseo A Martínez-García
- Department of Dermatology, Hospital Clínico Virgen de la Victoria, University of Malaga, Malaga, Spain
| | - Enrique Herrera-Ceballos
- Department of Dermatology, Hospital Clínico Virgen de la Victoria, University of Malaga, Malaga, Spain
| |
Collapse
|
23
|
Sahuquillo-Torralba A, Carretero G, Rivera R, Ferrándiz C, Daudén-Tello E, de la Cueva P, Gómez-García FJ, Belinchón I, Herrera-Acosta E, Ruiz-Genao D, Ferrán M, Alsina M, Sánchez-Carazo JL, Baniandrés O, Fernández-Freire LR, Vilar J, García-Donoso C, Carrascosa JM, Llamas-Velasco M, Herrera-Ceballos E, López-Estebaranz JL, Pujol-Marco C, Descalzo MÁ, García-Doval I. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study. J Am Acad Dermatol 2020; 82:738-741. [DOI: 10.1016/j.jaad.2019.07.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Revised: 07/03/2019] [Accepted: 07/06/2019] [Indexed: 01/08/2023]
|
24
|
de Gálvez MV, Aguilera J, Sánchez-Roldán C, Herrera-Acosta E, Herrera-Ceballos E. Water-Filtered Infrared Radiation Decreases the Generation of Photodermatoses Dependent on Ultraviolet and Visible Radiation. Photochem Photobiol 2018; 95:874-878. [PMID: 30447157 DOI: 10.1111/php.13049] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Accepted: 10/23/2018] [Indexed: 02/05/2023]
Abstract
The potential role of infrared radiation in photodermatoses has received very little attention, even though the main sources of radiation used for photobiological studies (UVA, UVB and visible light) include infrared radiation. The objective of the work was to assess whether infrared radiation is involved in the development of skin lesions in patients with different types of photodermatoses. Twenty patients with different photodermatoses were exposed to UVA, UVB and visible radiation using a high-pressure mercury UVA lamp, a fluorescent broadband UVB lamp, a tungsten bulb and a slide projector for visible radiation. Part of the radiation emitted by these lamps was water-filtered to block infrared radiation above 1300 nm. All 20 patients developed lesions when exposed to different light sources used for phototest. When exposed to same sources without infrared radiation, 17 patients (85%) did not develop any lesions and the other three (15%) developed less severe lesions than in the area exposed to unfiltered light. Our results show that infrared radiation was necessary for the development of skin lesions in 85% of the patients with photodermatoses in our study. We believe that infrared radiation studies should be included in standard photobiology protocols.
Collapse
Affiliation(s)
- María V de Gálvez
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
| | - José Aguilera
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
| | - Cristina Sánchez-Roldán
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain
| | - Enrique Herrera-Acosta
- Dermatology Service, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.,Dermatology Service, Vithas Xanit Hospital Internacional, Málaga, Spain
| | - Enrique Herrera-Ceballos
- Photobiological Dermatology Laboratory, Medical Research Center, Department of Dermatology and Medicine, Faculty of Medicine, University of Málaga, Málaga, Spain.,Dermatology Service, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain
| |
Collapse
|
25
|
Garcia-Doval I, Descalzo M, Mason K, Cohen A, Ormerod A, Gómez-García F, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths C, Stern R, Naldi L. Biological therapy for psoriasis and risk of cancer. Br J Dermatol 2018. [DOI: 10.1111/bjd.17166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
26
|
Garcia-Doval I, Descalzo M, Mason K, Cohen A, Ormerod A, Gómez-García F, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths C, Stern R, Naldi L. 银屑病的生物治疗和癌症风险. Br J Dermatol 2018. [DOI: 10.1111/bjd.17177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
27
|
Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern RS, Naldi L. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. Br J Dermatol 2018; 179:863-871. [PMID: 29723914 DOI: 10.1111/bjd.16715] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/23/2018] [Indexed: 12/15/2022]
Abstract
BACKGROUND Cancer risk following long-term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible. OBJECTIVES To assess a dose-response relationship between cumulative length of exposure to biological therapy and risk of cancer. METHODS Four national studies (a healthcare database from Israel, and prospective cohorts form Italy, Spain and the U.K. and Republic of Ireland) collaborating through Psonet (European Registry of Psoriasis) participated in these nested case-control studies, including nearly 60 000 person-years of observation. 'Cases' were patients who developed an incident cancer. Patients with previous cancers and benign or in situ tumours were excluded. Four cancer-free controls were matched to each case on year of birth, sex, geographic area and registration year. Follow-up for controls was censored at the date of cancer diagnosis for the matched case. Conditional logistic regression was performed by each registry. Results were pooled using random-effects meta-analysis. RESULTS A total of 728 cases and 2671 controls were identified. After matching, differences between cases and controls were present for the Charlson Comorbidity Index in all three registries, and in the prevalence of previous exposure to psoralen-ultraviolet A and smoking (the British Association of Dermatologists Biologic Interventions Register only). The risk of first cancers was not significantly associated with cumulative exposure to biologics (adjusted odds ratio per year of exposure 1·02, 95% confidence interval 0·92-1·13). Results were similar if squamous and basal cell carcinomas were included in the outcome. CONCLUSIONS Cumulative length of exposure to biological therapies in patients with psoriasis in real-world clinical practice does not appear to be linked to a higher risk of cancer after several years of use.
Collapse
Affiliation(s)
- I Garcia-Doval
- Research Unit, Fundación Piel Sana Academia Española de Dermatología y Venereología, Madrid, Spain.,Department of Dermatology, Complexo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain
| | - M A Descalzo
- Research Unit, Fundación Piel Sana Academia Española de Dermatología y Venereología, Madrid, Spain
| | - K J Mason
- Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K
| | - A D Cohen
- Department of Quality Measures and Research, Chief Physician Office, Clalit Health Services, Tel Aviv, Israel.,Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - A D Ormerod
- Division of Applied Medicine, Aberdeen University, Aberdeen, U.K
| | - F J Gómez-García
- Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - S Cazzaniga
- Centro Studi GISED, Fondazione per la Ricerca, Ospedale Maggiore, Bergamo, Italy
| | - I Feldhamer
- Department of Quality Measures and Research, Chief Physician Office, Clalit Health Services, Tel Aviv, Israel.,Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - H Ali
- Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K
| | - E Herrera-Acosta
- Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - C E M Griffiths
- Centre for Dermatology Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.,Dermatology Centre, Salford Royal NHS Foundation Trust, Salford, U.K
| | - R S Stern
- Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, U.S.A
| | - L Naldi
- Centro Studi GISED, Fondazione per la Ricerca, Ospedale Maggiore, Bergamo, Italy.,Department of Dermatology, AULSS8, Ospedale San Bortolo, Vicenza, Italy
| | | |
Collapse
|
28
|
Tejera-Vaquerizo A, Pérez-Cabello G, Marínez-Leborans L, Gallego E, Oliver-Martínez V, Martín-Cuevas P, Arias-Santiago S, Aneiros-Fernández J, Herrera-Acosta E, Traves V, Herrera-Ceballos E, Nagore E. Is mitotic rate still useful in the management of patients with thin melanoma? J Eur Acad Dermatol Venereol 2017; 31:2025-2029. [DOI: 10.1111/jdv.14485] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2017] [Accepted: 07/12/2017] [Indexed: 12/30/2022]
Affiliation(s)
- A. Tejera-Vaquerizo
- Servicio de Dermatología; Instituto de Biomedicina de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria/Universidad de Málaga; Málaga Spain
- Servicio de Dermatología; Instituto dermatológico Globalderm; Palma del Río Córdoba Spain
| | - G. Pérez-Cabello
- Servicio de Dermatología; Instituto de Biomedicina de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria/Universidad de Málaga; Málaga Spain
| | - L. Marínez-Leborans
- Servicio de Dermatología; Hospital General Universitario de Valencia; Valencia Spain
| | - E. Gallego
- Servicio de Anatomía Patológica; Instituto de Biomedicina de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria/Universidad de Málaga; Málaga Spain
| | - V. Oliver-Martínez
- Servicio de Dermatología; Hospital General Universitario de Valencia; Valencia Spain
| | - P. Martín-Cuevas
- Servicio de Dermatología; Instituto de Biomedicina de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria/Universidad de Málaga; Málaga Spain
| | - S. Arias-Santiago
- Unidad de Dermatología; Instituto de Investigaciones Biosanitarias IBS, Granada; Hospitales Universitarios de Granada/Universidad de Granada; Granada Spain
| | - J. Aneiros-Fernández
- Unidad de Anatomía Patológica; Instituto de Investigaciones Biosanitarias IBS, Granada; Hospitales Universitarios de Granada/Universidad de Granada; Granada Spain
| | - E. Herrera-Acosta
- Servicio de Dermatología; Instituto de Biomedicina de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria/Universidad de Málaga; Málaga Spain
| | - V. Traves
- Servicio de Anatomía Patológica; Instituto Valenciano de Oncología; Valencia Spain
| | - E. Herrera-Ceballos
- Servicio de Dermatología; Instituto de Biomedicina de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria/Universidad de Málaga; Málaga Spain
| | - E. Nagore
- Servicio de Dermatología; Instituto Valenciano de Oncología; Valencia Spain
| |
Collapse
|
29
|
Tejera-Vaquerizo A, Nagore E, Puig S, Robert C, Saiag P, Martín-Cuevas P, Gallego E, Herrera-Acosta E, Aguilera J, Malvehy J, Carrera C, Cavalcanti A, Rull R, Vilalta-Solsona A, Lannoy E, Boutros C, Benannoune N, Tomasic G, Aegerte P, Vidal-Sicart S, Palou J, Alos LL, Requena C, Traves V, Pla Á, Bolumar I, Soriano V, Guillén C, Herrera-Ceballos E. Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. Eur J Cancer 2015; 51:1780-93. [PMID: 26072362 DOI: 10.1016/j.ejca.2015.05.023] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2015] [Revised: 04/26/2015] [Accepted: 05/21/2015] [Indexed: 11/17/2022]
Abstract
INTRODUCTION In patients with primary cutaneous melanoma, there is generally a delay between excisional biopsy of the primary tumour and sentinel-node biopsy. The objective of this study is to analyse the prognostic implications of this delay. PATIENTS AND METHOD This was an observational, retrospective, cohort study in four tertiary referral hospitals. A total of 1963 patients were included. The factor of interest was the interval between the date of the excisional biopsy of the primary melanoma and the date of the sentinel-node biopsy (delay time) in the prognosis. The primary outcome was melanoma-specific survival and disease-free survival. RESULTS A delay time of 40 days or less (hazard ratio (HR), 1.7; confidence interval (CI), 1.2-2.5) increased Breslow thickness (Breslow ⩾ 2 mm, HR, > 3.7; CI, 1.4-10.7), ulceration (HR, 1.6; CI, 1.1-2.3), sentinel-node metastasis (HR, 2.9; CI, 1.9-4.2), and primary melanoma localised in the head or neck were independently associated with worse melanoma-specific survival (all P < 0.03). The stratified analysis showed that the effect of delay time was at the expense of the patients with a negative sentinel-node biopsy and without regression. CONCLUSION Early sentinel-node biopsy is associated with worse survival in patients with cutaneous melanoma.
Collapse
Affiliation(s)
- Antonio Tejera-Vaquerizo
- Servicio de Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain.
| | - Eduardo Nagore
- Department of Dermatology, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8, 46009 Valencia, Spain.
| | - Susana Puig
- Melanoma Unit, Servicio de Dermatología y Anatomía Patológica, Hospital Clínic, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain.
| | - Caroline Robert
- Department of Dermatology, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
| | - Philippe Saiag
- Service de dermatologie générale et oncologique, Hôpital Ambroise-Paré, Université de Versailles, Boulogne cedex, France.
| | - Paula Martín-Cuevas
- Servicio de Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain.
| | - Elena Gallego
- Servicio de Anatomía Patológica, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain.
| | - Enrique Herrera-Acosta
- Servicio de Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain.
| | - José Aguilera
- Servicio de Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain.
| | - Josep Malvehy
- Melanoma Unit, Servicio de Dermatología y Anatomía Patológica, Hospital Clínic, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain.
| | - Cristina Carrera
- Melanoma Unit, Servicio de Dermatología y Anatomía Patológica, Hospital Clínic, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain.
| | - Andrea Cavalcanti
- Department of Surgery, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
| | - Ramón Rull
- Departamento de Cirugía, Hospital Clínic, Universidad de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
| | - Antonio Vilalta-Solsona
- Melanoma Unit, Servicio de Dermatología y Anatomía Patológica, Hospital Clínic, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain.
| | - Emilie Lannoy
- Biostatistics and Epidemiology Unit, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
| | - Celine Boutros
- Department of Dermatology, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
| | - Naima Benannoune
- Department of Dermatology, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
| | - Gorana Tomasic
- Department of Pathology, Gustave Roussy Cancer Campus, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France.
| | - Philippe Aegerte
- Service de Biostatistique et Informatique Médicale, Hôpital Ambroise-Paré, Boulogne, France.
| | - Sergi Vidal-Sicart
- Servicio de Medicina Nuclear, Hospital Clínic Barcelona, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain.
| | - Josep Palou
- Melanoma Unit, Servicio de Dermatología y Anatomía Patológica, Hospital Clínic, Universidad de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain.
| | - L Lúcia Alos
- Departamento de Anatomía Patológica, Universidad de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
| | - Celia Requena
- Department of Dermatology, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8, 46009 Valencia, Spain.
| | - Víctor Traves
- Departamento de Anatomía Patológica, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8, 46009 Valencia, Spain.
| | - Ángel Pla
- Departamento de Otorrinolaringología, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8, 46009 Valencia, Spain.
| | - Isidro Bolumar
- Departamento de Cirugía, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8, 46009 Valencia, Spain.
| | - Virtudes Soriano
- Departamento de Oncología Médica, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8, 46009 Valencia, Spain.
| | - Carlos Guillén
- Department of Dermatology, Instituto Valenciano de Oncología, c/ Profesor Beltrán Báguena, 8, 46009 Valencia, Spain.
| | - Enrique Herrera-Ceballos
- Servicio de Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Boulevard Louis Pasteur, 32, 29071 Málaga, Spain.
| |
Collapse
|
30
|
Tejera-Vaquerizo A, Arias-Santiago S, Nagore E, Martín-Cuevas P, Orgaz-Molina J, Traves V, Herrera-Acosta E, Naranjo-Sintes R, Guillén C, Herrera-Ceballos E. Defining the dermoscopic characteristics of fast-growing cutaneous melanomas. Melanoma Res 2015; 25:269-72. [PMID: 25919929 DOI: 10.1097/cmr.0000000000000157] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A high growth rate in melanomas has been associated with a more aggressive phenotype and worse survival. The aim of this study was to define the dermoscopic characteristics associated with this type of cutaneous melanoma. We carried out a retrospective study of 132 cutaneous melanomas, analyzing certain clinical characteristics and the most important dermoscopic variables related to the melanomas. Fast-growing melanomas were considered to be those with a growth rate of more than 0.5 mm per month. Fast-growing melanomas more often lacked an atypical network, were symmetrical, presented ulceration, and were hypopigmented. The dermoscopic vascular pattern often showed atypical irregular vessels and milky-red areas. The association of these two is a specific characteristic. Fast-growing melanomas have a characteristic phenotype and dermoscopy can be useful for their identification.
Collapse
Affiliation(s)
- Antonio Tejera-Vaquerizo
- aUnidad de Gestión Clínica de Dermatología, Instituto de Biomedicina de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria/Universidad de Málaga, Málaga bServicio de Dermatología, Hospital Universitario San Cecilio cServicio de Dermatología dServicio de Anatomía Patológica, Instituto Valenciano de Oncología, Valencia, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Tejera-Vaquerizo A, Martín-Cuevas P, Gallego E, Herrera-Acosta E, Traves V, Herrera-Ceballos E, Nagore E. Predictors of Sentinel Lymph Node Status in Cutaneous Melanoma: A Classification and Regression Tree Analysis. Actas Dermo-Sifiliográficas (English Edition) 2015. [DOI: 10.1016/j.adengl.2015.01.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
32
|
Moreno-Ramírez D, Ojeda-Vila T, Ríos-Martín JJ, Ruiz-Villaverde R, de-Troya M, Sanz-Trelles A, Liébana RF, Martínez-de-Victoria JM, Aneiros-Fernández J, Naranjo-Sintes R, Amérigo J, Alcalde M, Zulueta T, Domínguez-Cruz JJ, Solís-García E, Tejera-Vaquerizo A, Martín-Castro AM, García-Mellado V, Martínez-García S, Martínez-García A, Herrera-Acosta E, Escámez PJ, Rodríguez-Fernández AM, Salvatierra-Cuenca J, Moreno-Giménez JC, Guerrero-Cauqui R, Armario-Hita JC, Nieto-Garcia A, Ferrándiz L. The role of accessibility policies and other determinants of health care provision in the initial prognosis of malignant melanoma: A cross-sectional study. J Am Acad Dermatol 2014; 71:507-15. [DOI: 10.1016/j.jaad.2014.04.049] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Revised: 04/16/2014] [Accepted: 04/17/2014] [Indexed: 11/30/2022]
|
33
|
Tejera-Vaquerizo A, Nagore E, Herrera-Acosta E, Martorell-Calatayud A, Martín-Cuevas P, Traves V, Herrera-Ceballos E. Prediction of Sentinel Lymph Node Positivity by Growth Rate of Cutaneous Melanoma. ACTA ACUST UNITED AC 2012; 148:577-84. [DOI: 10.1001/archdermatol.2011.2522] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
34
|
Suárez-Pérez J, Herrera-Acosta E, López-Navarro N, Vilchez-Márquez F, Prieto J, Bosch R, Herrera E. Pioderma gangrenoso: Presentación de 15 casos y revisión de la literatura. Actas Dermo-Sifiliográficas 2012; 103:120-6. [DOI: 10.1016/j.ad.2011.04.010] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2011] [Revised: 04/13/2011] [Accepted: 04/15/2011] [Indexed: 10/18/2022] Open
|
35
|
Tejera-Vaquerizo A, Nagore E, Meléndez JJ, López-Navarro N, Martorell-Calatayud A, Herrera-Acosta E, Traves V, Guillén C, Herrera-Ceballos E. Chronology of metastasis in cutaneous melanoma: growth rate model. J Invest Dermatol 2012; 132:1215-21. [PMID: 22217744 DOI: 10.1038/jid.2011.433] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In humans, it is not possible to obtain experimental evidence of when a cancer begins to metastasize. The purpose of this study was to estimate the time of onset of metastatic dissemination in cutaneous melanoma using a model based on its growth rate (GR). The critical time of onset of metastatic dissemination below which no cases of fatal melanomas were seen may be described with a potential function in which this time is inversely proportional to the GR. The critical time of development beyond which a melanoma may metastasize presents great variation. This time was just 1 month for those melanomas with a fast GR, whereas it was over 5 years for those with a very slow GR. Quantitatively, the fastest-growing melanomas began metastasizing with a greater thickness than the slowest-growing melanomas. A correlation exists between the critical time of onset of metastatic potential and the GR of the melanoma. These results may well have relevance to the understanding of mechanisms of tumor dissemination and for the design of future studies on melanomas, irrespective of whether they are basic studies on biomolecular mechamisms or clinical studies.
Collapse
Affiliation(s)
- Antonio Tejera-Vaquerizo
- Servicio de Dermatología, Facultad de Medicina, Hospital Universitario Virgen de Victoria, Málaga, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Suárez-Pérez J, López-Navarro N, Herrera-Acosta E. Grouped Papules and Plaques on the Lower Limbs. Actas Dermo-Sifiliográficas (English Edition) 2011. [DOI: 10.1016/j.adengl.2012.01.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
37
|
Suárez-Pérez J, López-Navarro N, Herrera-Acosta E. Pápulas y placas agrupadas en extremidades inferiores. Actas Dermo-Sifiliográficas 2011; 102:823-4. [DOI: 10.1016/j.ad.2011.03.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2011] [Accepted: 03/19/2011] [Indexed: 10/17/2022] Open
|
38
|
López N, Meyer-Gonzalez T, Herrera-Acosta E, Bosch R, Castillo R, Herrera E. Photodynamic therapy in the treatment of extensive Bowen's disease. J DERMATOL TREAT 2011; 23:428-30. [PMID: 21787214 DOI: 10.3109/09546634.2011.590789] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
BACKGROUND Surgical excision is the preferred method of eradicating Bowen´s disease (BD). Photodynamic therapy (PDT) has been successfully used for treatment of actinic keratosis, basal cell carcinoma, and BD. OBJECTIVE Our aim was to evaluate the efficacy and tolerability of PDT for treatment of extensive BD. METHOD Eighteen patients with 23 biopsy-proven BD lesions were treated with PDT. We defined as extensive those lesions large than 3 cm. Methyl aminolevulinate cream was applied for 3 h before illumination with an light emitting diode light source at a wavelength of 630 nm (energy density of 37 J/cm²). Treatment was repeated 1 week later. RESULTS After 12 weeks of treatment, 22 of 23 BD lesions (90%) showed complete clinical response. Only three lesions recurred after a follow-up period of 12 months. Cosmetic outcome at 12 months was good or excellent in 94% of patients. CONCLUSION Methyl aminolevulinate PDT is an effective treatment option for extensive BD with excellent cosmesis.
Collapse
Affiliation(s)
- Norberto López
- Department of Dermatology, University Hospital, School of Medicine, Malaga, Spain.
| | | | | | | | | | | |
Collapse
|
39
|
Contreras-Steyls M, López-Navarro N, Herrera-Acosta E, Castillo R, Ruiz del Portal G, Bosch RJ, Herrera E. [The current challenge of imported leprosy in Spain: a study of 7 cases]. Actas Dermosifiliogr 2011; 102:106-13. [PMID: 21334586 DOI: 10.1016/j.ad.2010.10.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2010] [Revised: 10/03/2010] [Accepted: 10/09/2010] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND although the foci of leprosy once present in Spain are now under control and almost inactive, isolated cases are still occasionally diagnosed. Meanwhile, population migration has brought about an increase in the incidence of cases corresponding to individuals from countries where leprosy is endemic, leading to changes in the epidemiology of this disease. OBJECTIVES the aim of this paper was to describe the clinical, epidemiologic, dermatologic, microbiologic, and therapeutic characteristics of cases of leprosy in our department in the last 5 years. MATERIAL AND METHODS we report the cases of imported leprosy seen in our department between 2004 and 2009. RESULTS seven patients with leprosy (3 men and 4 women; age range, 26-80 years) were diagnosed; 2 were cases of tuberculoid leprosy, 2 borderline tuberculoid leprosy, and 3 indeterminate. All patients acquired the disease in South American or South African countries, but were residing in Spain at the time of diagnosis. One patient was a Spaniard, from Malaga, who had worked as a missionary in Venezuela for 25 years. The presence of the bacterium by either Ziehl-Neelsen stain or bacilloscopy could not be demonstrated in any of the patients. CONCLUSIONS we would like to draw attention to the changes we have observed in the characteristics of cases of leprosy seen in our department, the majority of which are imported. It is important to maintain a clinical suspicion of leprosy in cases of granulomatous dermatitis, particularly in patients from countries where the disease is endemic.
Collapse
Affiliation(s)
- M Contreras-Steyls
- Servicio de Dermatología, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.
| | | | | | | | | | | | | |
Collapse
|
40
|
Tejera-Vaquerizo A, Lopez-Navarro N, Alcaide-Martin A, Herrera-Acosta E, Herrera-Ceballos E. Correlation of the growth rate of melanoma with the temporal appearance of metastasis. J Eur Acad Dermatol Venereol 2011; 25:366-7. [DOI: 10.1111/j.1468-3083.2010.03723.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Contreras-Steyls M, Herrera-Acosta E, Moyano B, Herrera E. [Primary melanoma with multiple skin metastases]. Actas Dermosifiliogr 2011; 102:226-9. [PMID: 21288499 DOI: 10.1016/j.ad.2010.06.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2010] [Revised: 06/20/2010] [Accepted: 06/22/2010] [Indexed: 10/18/2022] Open
|
42
|
Contreras-Steyls M, Herrera-Acosta E, Moyano B, Herrera E. Primary Melanoma With Multiple Skin Metastases. Actas Dermo-Sifiliográficas (English Edition) 2011. [DOI: 10.1016/s1578-2190(11)70793-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
43
|
Contreras-Steyls M, López-Navarro N, Herrera-Acosta E, Castillo R, Ruiz del Portal G, Bosch R, Herrera E. The Current Challenge of Imported Leprosy in Spain: A Study of 7 Cases. Actas Dermo-Sifiliográficas (English Edition) 2011. [DOI: 10.1016/s1578-2190(11)70767-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
44
|
Meyer T, Lopez-Navarro N, Herrera-Acosta E, Gallego E, Bosch RJ, Herrera E. Human immunodeficiency virus (HIV)-associated eosinophilic folliculitis and follicular mucinosis in a black woman. Int J Dermatol 2010; 49:1308-10. [DOI: 10.1111/j.1365-4632.2009.04257.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Meyer T, López-Navarro N, Herrera-Acosta E, Jose A, Herrera E. Erosive pustular dermatosis of the scalp: a successful treatment with photodynamic therapy. Photodermatology, Photoimmunology & Photomedicine 2010; 26:44-5. [DOI: 10.1111/j.1600-0781.2009.00478.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
46
|
Meyer-Gonzalez T, Alcaide-Martin A, Contreras-Steyls M, Mendiola M, Herrera-Acosta E, Herrera E. Pigmented mammary Paget disease mimicking cutaneous melanoma. Int J Dermatol 2010; 49:59-61. [DOI: 10.1111/j.1365-4632.2009.04318.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
López-Navarro N, Alcaide A, Gallego E, Herrera-Acosta E, Gallardo M, Bosch RJ, Herrera E. Amicrobial pustulosis of the folds associated with Hashimotoâs thyroiditis. Clin Exp Dermatol 2009; 34:e561-3. [DOI: 10.1111/j.1365-2230.2009.03370.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
48
|
Márquez-Balbás G, Iglesias M, Herrera-Acosta E, Vidal-Olmo I, Guilabert A, Mascaró-Galy JM, Umbert P. [Amicrobial pustulosis of the folds: report of a new case and review of literature]. Actas Dermosifiliogr 2009; 100:710-714. [PMID: 19775550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
Amicrobial pustulosis of the folds is a rare disorder characterized by a recurrent sterile pustular rash mainly affecting the skinfolds, scalp, and periorificial regions such as around the external auditory meatus. Few cases have been reported in the literature, most of them occurring women and all of them associated with some immunological disorder, the most common being lupus erythematosus. We present a new case of amicrobial pustulosis of the folds in a woman; the only immunologic abnormality detected was an elevation of immunoglobulin E. We have also reviewed the 35 cases reported in the literature.
Collapse
Affiliation(s)
- G Márquez-Balbás
- Servicio de Dermatología, Hospital Universitario Sagrat Cor, Barcelona, España.
| | | | | | | | | | | | | |
Collapse
|
49
|
Márquez-Balbás G, Iglesias M, Herrera-Acosta E, Vidal-Olmo I, Guilabert A, Mascaró-Galy J, Umbert P. Amicrobial Pustulosis of the Folds: Report of a New Case and Review of the Literature. Actas Dermo-Sifiliográficas (English Edition) 2009. [DOI: 10.1016/s1578-2190(09)70154-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
50
|
López-Navarro N, Alcaide A, Gallego E, Herrera-Acosta E, Castillo R, Herrera E. Dermatoscopy in the diagnosis of combined desmoplastic trichoepithelioma and naevus. Clin Exp Dermatol 2009; 34:e395-6. [DOI: 10.1111/j.1365-2230.2009.03369.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|